sr141716 has been researched along with bradykinin in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 9 (75.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kendall, DA; Randall, MD | 1 |
| Fulton, D; Quilley, J | 1 |
| Baker, PN; Dunn, WR; Kendall, DA; Kenny, LC; Randall, MD | 1 |
| Caillé, S; Parsons, LH | 1 |
| Aberman, J; Betz, AJ; Ishiwari, K; Makriyannis, A; McLaughlin, PJ; Salamone, JD; Swezey, L; Tardif, DJ; Winston, K; Wisniecki, A | 1 |
| Aumiller, J | 1 |
| Henzen, C | 1 |
| Scheen, AJ; Van Gaal, LF | 1 |
| Manzato, E; Marchiori, M; Zambon, A | 1 |
| Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V | 1 |
| De Felice, M; Fioravanti, B; Gardell, LR; Ibrahim, M; King, T; Lai, J; Luo, MC; Malan, TP; Medler, KA; Ossipov, MH; Porreca, F; Stucky, CL; Vanderah, TW; Yamamura, HI | 1 |
| Kemmer, M; Kreis, ME; Li, Y; Müller, M; Qian, G; Sibaev, A; Storr, M; Yüce, B | 1 |
2 review(s) available for sr141716 and bradykinin
| Article | Year |
|---|---|
[Internal medicine--update 2006].
Topics: Adrenal Gland Neoplasms; Bradykinin; Carotid Stenosis; Clinical Trials as Topic; Contrast Media; Endarterectomy, Carotid; Esophageal and Gastric Varices; Female; Heart Failure; Humans; Hyperglycemia; Hypertension; Hyperthyroidism; Internal Medicine; Male; Middle Aged; Osteitis Deformans; Piperidines; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Renal Insufficiency; Rimonabant; Risk Factors; Stents; Stethoscopes; Weight Loss | 2007 |
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss | 2007 |
1 trial(s) available for sr141716 and bradykinin
| Article | Year |
|---|---|
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss | 2007 |
10 other study(ies) available for sr141716 and bradykinin
| Article | Year |
|---|---|
Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation.
Topics: Animals; Arachidonic Acids; Biological Factors; Bradykinin; Calcium Channel Blockers; Cannabinoid Receptor Modulators; Cannabinoids; Clotrimazole; Coronary Vessels; Endocannabinoids; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Piperidines; Polyunsaturated Alkamides; Potassium Channel Blockers; Pyrazoles; Quaternary Ammonium Compounds; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Vasodilation | 1997 |
Evidence against anandamide as the hyperpolarizing factor mediating the nitric oxide-independent coronary vasodilator effect of bradykinin in the rat.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Biological Factors; Bradykinin; Coronary Vessels; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Endocannabinoids; Male; Nitric Oxide; Piperidines; Polyunsaturated Alkamides; Potassium Channel Blockers; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Vasodilation | 1998 |
The role of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Arteries; Biological Factors; Bradykinin; Cannabinoids; Carbenoxolone; Clotrimazole; Cyclooxygenase Inhibitors; Endothelium, Vascular; Fatty Acids, Monounsaturated; Female; Gap Junctions; Glycyrrhetinic Acid; Humans; In Vitro Techniques; Indomethacin; Myometrium; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Piperidines; Pregnancy; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Vasoconstrictor Agents; Vasodilation | 2002 |
SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats.
Topics: Animals; Area Under Curve; Behavior, Animal; Bradykinin; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Heroin; Male; Microdialysis; Narcotics; Nucleus Accumbens; Piperidines; Pyrazoles; Rats; Rats, Wistar; Reinforcement Schedule; Rimonabant; Self Administration; Time Factors | 2003 |
The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats.
Topics: Animals; Appetite; Bradykinin; Cannabinoids; Dose-Response Relationship, Drug; Feeding Behavior; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptors, Drug; Reinforcement Schedule; Rimonabant | 2003 |
[Endocannabinoids receptor blocker lets tumble not only money. A drug against metabolic syndrome?].
Topics: Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Metabolic Syndrome; Piperidines; Placebos; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Weight Loss | 2004 |
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy].
Topics: Atherosclerosis; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Meta-Analysis as Topic; Obesity; Piperidines; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Sex Factors | 2008 |
[Pharmacological therapy of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; Economics, Pharmaceutical; Humans; Lactones; Lipase; Meta-Analysis as Topic; Obesity; Orlistat; Piperidines; Practice Guidelines as Topic; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Time Factors; Weight Loss | 2008 |
Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists.
Topics: Analysis of Variance; Animals; Behavior, Animal; Bradykinin; Calcitonin Gene-Related Peptide; Calcium; Capsaicin; Cell Line, Tumor; Dose-Response Relationship, Drug; Galanin; Gene Expression Regulation; Male; Mice; Mice, Inbred ICR; Mice, Knockout; Morphine; Narcotics; Nerve Fibers, Unmyelinated; Neuroblastoma; Pain; Pain Measurement; Pain Threshold; Piperidines; Pyrazoles; Rats; Reaction Time; Receptor, Cannabinoid, CB1; Rimonabant; Stimulation, Chemical; Sulfonamides; TRPV Cation Channels | 2008 |
Cannabinoid 1 receptors modulate intestinal sensory and motor function in rat.
Topics: Animals; Benzoxazines; Bradykinin; Dose-Response Relationship, Drug; Electrophysiology; Enteric Nervous System; Gastrointestinal Motility; Intestines; Male; Morpholines; Motor Neurons; Muscle Contraction; Myenteric Plexus; Naphthalenes; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Sensory Receptor Cells; Serotonin | 2010 |